Vutrisiran First in China: ATTR-CM Treatment at Lecheng

There is a particular kind of helplessness that comes with diagnosing a disease for which, for years, you have had little to offer beyond supportive care. I have felt it with ATTR-CM patients — men and women, mostly in their sixties and seventies, who arrive in clinic with swollen legs, breathlessness on minimal exertion, and a heart that has quietly stiffened under the weight of amyloid deposits. They have often been treated for heart failure for years. Some have been told they have hypertensive heart disease. Others have undergone carpal tunnel surgery, never realizing that the wrist surgery and the failing heart were two manifestations of the same underlying process.

For a long time, my role was to confirm the diagnosis, explain the prognosis, and try to keep them comfortable. It was not enough. It never is.

On September 9, 2026, something changed. Under the guidance of Dr. Jin Wei’s team at Ruijin Hospital Shanghai, and through the “pioneering pilot” policy of the Boao Lecheng International Medical Tourism Pilot Zone, Ruijin Hainan Hospital completed China’s first clinical use of Vutrisiran in a patient with ATTR-CM. I was not the treating physician — but as someone who works within the Lecheng ecosystem and has followed this disease closely, I felt the weight of the moment. It was the kind of milestone that shifts how we think about what is possible.

ATTR-CM is caused by the deposition of misfolded transthyretin (TTR) protein in the myocardium. Over time, these amyloid fibrils stiffen the heart muscle, impairing its ability to relax and fill with blood — a condition known as restrictive cardiomyopathy. As the disease progresses, it leads to heart failure, arrhythmias, and, ultimately, death.

The problem is that the early symptoms of ATTR-CM are almost indistinguishable from those of far more common cardiac conditions. Shortness of breath, fatigue, leg swelling, and exercise intolerance — these are the everyday complaints of millions of older adults with hypertension or coronary artery disease. A 2025 ESC presentation highlighted that ATTR-CM has a misdiagnosis rate of 26% across four European countries. Other systematic reviews have reported misdiagnosis rates ranging from 34% to 57%. The median delay from symptom onset to diagnosis is 3.4 years for wild-type ATTR-CM and 2.6 years for the hereditary form.

What makes this delay so consequential is that ATTR-CM is not a benign condition. Without disease-modifying therapy, median survival is two to six years. Every year of diagnostic delay is associated with a 7% higher risk of heart failure hospitalization or death. Time lost is myocardium lost.

There is also a cultural dimension to the underdiagnosis in China. Many patients and families attribute declining exercise capacity to “just getting older.” Physicians, faced with an elderly patient with heart failure, often focus on the more common diagnoses. The extracardiac clues — bilateral carpal tunnel syndrome, lumbar spinal stenosis, peripheral neuropathy — are frequently dismissed as isolated musculoskeletal issues, when they are in fact early warning signs of systemic amyloidosis.

Vutrisiran, marketed as Amvuttra, represents a fundamentally different approach to treating ATTR-CM. It is a small interfering RNA (siRNA) therapeutic that targets the root cause of the disease by silencing the production of TTR in the liver. Administered as a subcutaneous injection once every three months, it rapidly reduces both mutant and wild-type transthyretin levels, thereby reducing the formation of the amyloid fibrils that damage the heart.

The efficacy data from the HELIOS-B Phase III trial are compelling. In the trial, which enrolled 655 patients with ATTR-CM, vutrisiran demonstrated a 28% reduction in the composite of all-cause mortality and recurrent cardiovascular events over 36 months compared to placebo. A meta-analysis of RNA-based therapies in ATTR-CM, including vutrisiran, showed a significant reduction in all-cause mortality with a risk ratio of 0.71. In a separate analysis, vutrisiran ranked best for improvement in six-minute walk distance and showed the largest reductions in NT-proBNP and troponin I — biomarkers that reflect cardiac stress and injury.

What distinguishes vutrisiran from the traditional standard of care, tafamidis, is its mechanism. Tafamidis is a TTR stabilizer — it prevents the tetrameric TTR protein from dissociating into monomers that can misfold and aggregate. Vutrisiran, by contrast, is a “silencer.” It stops the problem at its source by preventing the liver from producing the protein in the first place. The network meta-analysis published in JACC in 2026 found that silencers, led by vutrisiran, provide robust improvements in biomarkers and functional capacity, while stabilizers, led by tafamidis, maximize quality of life. These findings support phenotype-guided selection, and they underscore the fact that we now have more than one tool in the toolbox.

Vutrisiran was approved by the U.S. FDA in March 2025 for the treatment of wild-type or hereditary ATTR-CM in adults, making it the first and only RNAi therapeutic approved for this indication. The recommended dosage is 25 mg administered subcutaneously once every three months.

The patient treated at Ruijin Hainan Hospital was a man who met the clinical criteria for ATTR-CM. His case was reviewed by Dr. Jin Wei’s team, and the decision to proceed with vutrisiran was made after a careful assessment of his disease status and eligibility. The treatment itself was administered as a subcutaneous injection — a procedure that, in clinical practice, takes only minutes and can be performed in an outpatient setting.

What makes this case significant is not the complexity of the procedure — it is the fact that it happened at all. Vutrisiran is not yet approved by China’s National Medical Products Administration for general use. It is available in Lecheng only through the pilot zone’s special access policy, which allows innovative drugs approved by major international regulators to be used clinically in China before they receive full national approval. This is the same framework that has brought dozens of other breakthrough therapies to Chinese patients — from cell and gene therapies to rare disease drugs — years ahead of their otherwise expected approval timelines.

For the patient, the treatment offers something that previously did not exist in China: a disease-modifying therapy that targets the underlying cause of ATTR-CM, rather than simply managing its symptoms. The injection is administered once every three months, which means four clinic visits per year — a schedule that is far less burdensome than the frequent hospitalizations that often characterize the lives of patients with advanced heart failure.

I spoke with a colleague who was involved in the case. He described the moment after the injection was administered — the patient’s expression, the family’s quiet relief. “It is not a cure,” he said. “But for the first time, we are treating the disease itself, not just the consequences. That matters.”

ATTR-CM has historically been described as a rare disease, but that perception is changing. As diagnostic tools have improved and awareness has grown, it has become clear that ATTR-CM is far more common than previously recognized — particularly among older adults with heart failure with preserved ejection fraction. In the United States alone, an estimated 150,000 individuals are living with the condition. In China, the true prevalence is unknown, but as the population ages and diagnostic capabilities expand, the number of patients identified is likely to rise substantially.

For those patients, the availability of vutrisiran in Lecheng represents a genuine shift. It means that a diagnosis of ATTR-CM no longer has to be a sentence to a slow and steady decline. It means that there is a therapy that can be started early, that targets the biology of the disease, and that has been shown in randomized trials to reduce mortality and cardiovascular events. It means that families who have watched a loved one struggle with breathlessness and fatigue now have a concrete option to discuss with their physicians.